纳米粒子在水凝中的输送系统,用于连续释放两个药物
Demian van Straten1, Jaime Fernández Bimbo1, Wim E Hennink2
1CDL Research, University Medical Center Utrecht, 3584CX Utrecht, The Netherlands.
Pharmaceutics
|January 25, 2025
概括
这项研究开发了一种用于局部质母细胞瘤治疗的新型水凝. 水凝提供了顺序释放的甲和甲酸盐,以有效地管理大脑.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 神经瘤学神经瘤学
背景情况:
- 质母细胞瘤会导致致命的大脑,通常需要高剂量的系统性德克萨米他,并会产生严重的副作用.
- 局部药物输送旨在提高治疗效果,减少质母细胞瘤患者的全身毒性.
研究的目的:
- 为了研究一种可生物降解的德克斯-基乙基甲酸盐 (dex-HEMA) 水凝,用于局部,持续的德克萨米他输送.
- 通过聚合物微粒和通过脂质体结合甲酸,以连续释放药物.
主要方法:
- 合成和特征的聚乙烯甘醇-b-聚-N-2-基烯基甲基胺 (mPEG-b-p-HPMA-Bz) 杂质装载着德克萨米他.
- 封装的甲酸进入脂质体.
- 在德克斯-HEMA溶液中分散微粒和脂质体,然后进行光聚合以形成水凝.
- 从水凝中确定药物释放动力学和机制.
主要成果:
- 纳米粒子 (和脂质体) 在水凝网络中成功固定.
- 德克萨米他在两周内从细胞中释放出来.
- 在水凝降解后15天后,甲酸盐从脂质体中释放出来,导致双相释放.
结论:
- 开发的水凝系统使得德甲和德甲酸的顺序,局部释放成为可能.
- 该平台显示了治疗质母细胞瘤相关的内胀的潜力,并提高了安全性和有效性.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
Modified-Release Drug Delivery Systems: Classification
315
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
315
Modified-Release Drug Delivery Systems: Rate-Programmed I
172
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
172
Modified-Release Drug Delivery Systems: Stimuli-Activated
177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160


